13D/13G Filings - Lynx1 Capital Management LP

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Goto Prev, 0, 1, 2, Next
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-02-14
09:21 am
Purchase
2023-12-3113GC4 Therapeutics, Inc.
CCCC
Lynx1 Capital Management LP3,134,396
6.400%
12,177increase
(+0.39%)
Filing
History
2024-02-14
09:20 am
Purchase
2023-12-3113GStoke Therapeutics, Inc.
STOK
Lynx1 Capital Management LP2,956,918
6.600%
292,760increase
(+10.99%)
Filing
History
2024-02-14
09:20 am
Purchase
2023-12-3113GCabaletta Bio, Inc.
CABA
Lynx1 Capital Management LP2,139,644
4.990%
2,139,644increase
(New Position)
Filing
History
2024-02-14
09:19 am
Purchase
2023-12-3113GPieris Pharmaceuticals, Inc.
PIRS
Lynx1 Capital Management LP122,198
9.900%
51,841increase
(+73.68%)
Filing
History
2024-02-14
09:19 am
Sale
2023-12-3113GNeoleukin Therapeutics, Inc.
NLTX
Lynx1 Capital Management LP46
0.100%
-114,511decrease
(-99.96%)
Filing
History
2024-02-14
09:18 am
Sale
2023-12-3113GBionomics Limited
BNOX
Lynx1 Capital Management LP12,364,575
7.800%
-533,400decrease
(-4.14%)
Filing
History
2023-11-13
4:55 pm
Purchase
2023-11-0113GC4 Therapeutics, Inc.
CCCC
Lynx1 Capital Management LP3,122,219
6.300%
3,122,219increase
(New Position)
Filing
History
2023-11-06
4:55 pm
Purchase
2023-10-2613GStoke Therapeutics, Inc.
STOK
Lynx1 Capital Management LP2,664,158
6.000%
2,664,158increase
(New Position)
Filing
History
2023-10-30
4:21 pm
Purchase
2023-09-2913GBionomics Limited
BNOX
Lynx1 Capital Management LP12,897,975
8.200%
12,897,975increase
(New Position)
Filing
History
2023-06-02
4:56 pm
Purchase
2023-05-3113GTScan Therapeutics, Inc.
TCRX
Lynx1 Capital Management LP5,224,600
12.200%
5,224,600increase
(New Position)
Filing
History
2023-02-14
4:07 pm
Purchase
2022-12-3113GCabaletta Bio, Inc.
CABA
Lynx1 Capital Management LP2,825,976
9.700%
465,664increase
(+19.73%)
Filing
History
2023-02-14
4:06 pm
Purchase
2022-12-3113GPassage Bio, Inc.
PASG
Lynx1 Capital Management LP167,796
6.200%
30,175increase
(+21.93%)
Filing
History
2023-02-14
4:06 pm
Purchase
2022-12-3113GPieris Pharmaceuticals, Inc.
PIRS
Lynx1 Capital Management LP70,357
7.600%
22,550increase
(+47.17%)
Filing
History
2023-02-14
4:05 pm
Purchase
2022-12-3113GAlpine Immune Sciences, Inc.
ALPN
Lynx1 Capital Management LP3,126,173
6.800%
1,588,828increase
(+103.35%)
Filing
History
2023-01-23
4:28 pm
Purchase
2023-01-1313GKinnate Biopharma Inc.
KNTE
Lynx1 Capital Management LP2,213,178
5.000%
2,213,178increase
(New Position)
Filing
History
2023-01-23
4:23 pm
Purchase
2023-01-1313GPardes Biosciences, Inc.
PRDS
Lynx1 Capital Management LP3,139,202
5.000%
3,139,202increase
(New Position)
Filing
History
2022-12-30
4:29 pm
Purchase
2022-12-2013GNeoleukin Therapeutics, Inc.
NLTX
Lynx1 Capital Management LP114,557
5.380%
114,557increase
(New Position)
Filing
History
2022-10-31
4:40 pm
Purchase
2022-10-2013GCabaletta Bio, Inc.
CABA
Lynx1 Capital Management LP2,360,312
8.140%
2,360,312increase
(New Position)
Filing
History
2022-10-24
4:57 pm
Purchase
2022-10-1313GPieris Pharmaceuticals, Inc.
PIRS
Lynx1 Capital Management LP47,808
5.100%
47,808increase
(New Position)
Filing
History
2022-09-29
4:30 pm
Purchase
2022-09-1913GPassage Bio, Inc.
PASG
Lynx1 Capital Management LP137,621
5.100%
137,621increase
(New Position)
Filing
History
Goto Prev, 0, 1, 2, Next